Patent · US Active

Modified oligonucleotides and methods of use

US12077757B2 · kind B2 · utility

0Cited by

14References

15Claims

0Family size

Assignee

Janssen Pharmaceuticals, Inc. · BE

Inventors

Sergei Gryaznov · San Mateo, US
Leonid Beigelman · San Mateo, US
Antitsa Dimitrova Stoycheva · Rue de l'Église, US
Saul Martinez Montero · San Bruno, US
Jin Hong · Pacifica, US
Rajendra K. Pandey · Foster City, US
Vivek Kumar Rajwanshi · Cupertino, US
Lakshmipathi Pandarinathan · Boston, US
Yi Jin · Winnipeg, CA
Bharat Baral · Vacaville, US

Key dates

Filing date	Oct 5, 2020
Grant date	Sep 3, 2024
Priority date	—
Expiry date	Jun 29, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/32
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Modified oligonucleotides comprising modifications at the 2′ and/or 3′ position(s) along with methods of making and use, e.g., against HBV are disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.